Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Jose F. Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher Espelin, Neeraj Kohli, Bahar Matin, Yulius Setiady, Michael L. Miller, Thomas A. Keating, Ravi Chari, Jan Pinkas, Richard Gregory, Greg M. Thurber

Mol Cancer Ther (2021) 20 (1): 203–212.

https://doi.org/10.1158/1535-7163.MCT-20-0451

Published: 05 January 2021

View articletitled, Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Includes: Supplementary data

Journal Articles

Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).

Michael Miller, Nathan Fishkin, Wei Li, Emily Reid, Katie Archer, Erin Maloney, Yelena Kovtun, Gregory Jones, Megan Ellis, Rajeeva Singh, Kathleen Whiteman, Jan Pinkas, Ravi Chari

Mol Cancer Ther (2013) 12 (11_Supplement): C160.

https://doi.org/10.1158/1535-7163.TARG-13-C160

Published: 01 November 2013

View articletitled, Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).

Journal Articles

Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).

Rajeeva Singh, Nathan Fishkin, Yelena Kovtun, Gregory Jones, Jose Ponte, Hans Erickson, Erica Hong, Yulius Setiady, Andre Dandeneau, Katharine Lai, Jennifer Coccia, Leanne Lanieri, Juliet Bouchard, Karen Veale, Ravi Chari, Wayne Widdison

Mol Cancer Ther (2013) 12 (11_Supplement): C164.

https://doi.org/10.1158/1535-7163.TARG-13-C164

Published: 01 November 2013

View articletitled, Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).

Journal Articles

Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.

Kathleen Whiteman, Holly Johnson, Alan Wilhelm, Michael Miller, Wei Li, Emily Reid, Katie Archer, Nathan Fishkin, Andre Dandeneau, Erin Maloney, Jan Pinkas, Ravi Chari

Mol Cancer Ther (2013) 12 (11_Supplement): C162.

https://doi.org/10.1158/1535-7163.TARG-13-C162

Published: 01 November 2013

View articletitled, Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.

Journal Articles

Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Emin Oroudjev, Manu Lopus, Leslie Wilson, Charlene Audette, Carmela Provenzano, Hans Erickson, Yelena Kovtun, Ravi Chari, Mary Ann Jordan

Mol Cancer Ther (2010) 9 (10): 2700–2713.

https://doi.org/10.1158/1535-7163.MCT-10-0645

Published: 10 October 2010

View articletitled, Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Journal Articles

Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

Manu Lopus, Emin Oroudjev, Leslie Wilson, Sharon Wilhelm, Wayne Widdison, Ravi Chari, Mary Ann Jordan

Mol Cancer Ther (2010) 9 (10): 2689–2699.

https://doi.org/10.1158/1535-7163.MCT-10-0644

Published: 10 October 2010

View articletitled, Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

Includes: Supplementary data

Journal Articles

Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents

Michael Miller, Nathan Fishkin, Wei Li, Barbara Leece, Michele Mayo, Gregory Jones, Emily Reid, Katie Archer, Erin Maloney, Yelena Kovtun, Jan Pinkas, Rajeeva Singh, Ravi Chari

Mol Cancer Ther (2009) 8 (12_Supplement): B126.

https://doi.org/10.1158/1535-7163.TARG-09-B126

Published: 10 December 2009

View articletitled, Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents

Journal Articles

Abstract B120: Designing potent antibody‐drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity

Erin Maloney, Nathan Fishkin, Ravi Chari, Rajeeva Singh

Mol Cancer Ther (2009) 8 (12_Supplement): B120.

https://doi.org/10.1158/1535-7163.TARG-09-B120

Published: 10 December 2009

View articletitled, Abstract B120: Designing potent antibody‐drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity

Journal Articles

Linker selection in antibody-maytansinoid conjugates impacts bystander killing in mouse xenograft models

Hans Erickson, Michele Mayo, Wayne Widdison, Charlene Audette, Yelena Kovtun, Ravi Chari, Robert Lutz, Rajeeva Singh

Mol Cancer Ther (2007) 6 (11_Supplement): A86.

Published: 01 November 2007

View articletitled, Linker selection in antibody-maytansinoid conjugates impacts bystander killing in mouse xenograft models

Journal Articles

Linker-dependent metabolites of antibody-maytansinoid conjugates in livers of CD-1 mice

xiuxia sun, Hans Erickson, wayne Widdison, Michele mayo, Robert Lutz, Ravi Chari, Rajeeva Singh

Mol Cancer Ther (2007) 6 (11_Supplement): B100.

Published: 01 November 2007

View articletitled, Linker-dependent metabolites of antibody-maytansinoid conjugates in livers of CD-1 mice

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).

Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).

Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.

Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents

Abstract B120: Designing potent antibody‐drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity

Linker selection in antibody-maytansinoid conjugates impacts bystander killing in mouse xenograft models

Linker-dependent metabolites of antibody-maytansinoid conjugates in livers of CD-1 mice

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only